Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05655520 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
NCT05655520 is a Phase 3 study that was terminated before completion, run by Supernus Pharmaceuticals. The registered enrollment target is 153 participants.
The verdict
NCT05655520, a Phase 3 study, was terminated before completion, sponsored by Supernus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
Interventions
- DRUG SAGE-718
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2025-01-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05655520
The ClinicalTrials.gov registry entry for NCT05655520 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAGE-718 is the first listed.
NCT05655520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05655520 about?
NCT05655520 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease". The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)
What is the current status of trial NCT05655520?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2022-12-14. Estimated completion is 2025-01-20.
What interventions are being tested in trial NCT05655520?
The interventions under investigation include: SAGE-718 (DRUG).
Who is sponsoring clinical trial NCT05655520?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.